Cervidil (Dinoprostone Vaginal) - Drug Interactions, Contraindications, Overdosage

DRUG INTERACTIONS

2. Drug Interactions: Cervidil may augment the activity of oxytocic agents and their concomitant use is not recommended. A dosing interval of at least 30 minutes is recommended for the sequential use of oxytocin following the removal of the dinoprostone vaginal insert. No other drug interactions have been identified.

OVERDOSAGE

Cervidil is used as a single dosage in a single application. Overdosage is usually manifested by uterine hyperstimulation which may be accompanied by fetal distress and is responsive to removal of the insert. Other treatment must be symptomatic since, to date, clinical experience with prostaglandin antagonists is insufficient.

The use of beta-adrenergic agents should be considered in the event of undesirable increased uterine activity.

CONTRAINDICATIONS

Cervidil is contraindicated in:

• * Patients with known hypersensitivity to prostaglandins.
• * Patients in whom there is clinical suspicion or definite evidence of fetal distress where delivery is not imminent.
• * Patients with unexplained vaginal bleeding during this pregnancy.
• * Patients in whom there is evidence or strong suspicion of marked cephalopelvic disproportion.
• *

  Patients in whom oxytocic drugs are contraindicated or when prolonged contraction of the uterus may be detrimental to fetal safety or uterine integrity, such as previous cesarean section or major uterine surgery (see PRECAUTIONS and ADVERSE REACTIONS ).

• * Patients already receiving intravenous oxytocic drugs.
• * Multipara with 6 or more previous term pregnancies.